Prostate cancer cell phenotypes based on AGR2 and CD10 expression

Modern Pathology

Volumn 26, Issue 6, 2013, Pages 849-859

  Ho, Melissa E ^a,b   Quek, Sue Ing ^a,b   True, Lawrence D ^b   Morrissey, Colm ^a   Corey, Eva ^a   Vessella, Robert L ^a,c   Dumpit, Ruth ^d   Nelson, Peter S ^d   Maresh, Erin L ^e   Mah, Vei ^e   Alavi, Mohammed ^e   Kim, Sara R ^e   Bagryanova, Lora ^e   Horvath, Steve ^e   Chia, David ^e   Goodglick, Lee ^e   Liu, Alvin Y ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AGR2; bone and soft tissue metastases; cancer cell phenotypes; CD10; patient stratification; prostate cancer; xenografts

Indexed keywords

ANTERIOR GRADIENT 2; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SOFT TISSUE METASTASIS; TISSUE MICROARRAY;

EID: 84878523707     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.238     Document Type: Article

References (34)

1. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostatespecific antigen leveloor 4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
2. Yu JB, Makarov DV, Sharma R, et al. Validation of the Partin nomogram for prostate cancer in a national sample. J Urol 2010;183:105-111.
3. Zhang JS, Gong A, Cheville JC, et al. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005;43:249-259.
4. Pascal LE, Vêncio RZN, Page LS, et al. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer 2009;9:452.
5. Maresh EL, Mah V, Alavi M, et al. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer 2010;10:680.
6. Bu H, Bormann S, Schafer G, et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 2011;71:575-587.
7. Osman I, Yee H, Taneja SS, et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004;10:4096-4100.
8. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 2004;165:1543-1556.
9. Dall'Era MA, True LD, Siegel AF, et al. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 2007;7:3.
10. Fleischmann A, Rocha C, Saxer-Sekulic N, et al. High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Arch 2011;458:741-748.
11. Fleischmann A, Schlomm T, Huland H, et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008;14:7838-7842.
12. Dall'Era MA, Oudes A, Martin DB, et al. Identification of HSP27 and HSP70 as CD10 binding proteins in prostate cancer cells. Prostate 2007;67:714-721.
13. Seligson DB, Hongo F, Huerta-Yepez S, et al. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 2007;13:6056-6063.
14. Wayner EA, Quek S, Ahmad R, et al. Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. Prostate 2012;72: 1023-1034.
15. Coleman IM, Kiefer JA, Brown LG, et al. Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 2006;8:862-878.
16. Corey E, Vessella RL. Xenograft models of human prostate cancer, In: Chung LW, Isaacs WB, Simons JWeds) Prostate Cancer: Biology, Genetics and the New Therapeutics. Humana Press: Totowa, NJ; 2007, pp 3-31.
17. Sun S, Sprenger CCT, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-2730.
18. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-653.
19. Sharma A, Yeow WS, Ertel A, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120:4478-4492.
20. Pascal LE, Vêncio RZN, Vessella RL, et al. Lineage relationship of prostate cancer cell types based on gene expression. BMC Med Genomics 2011;4:46.
21. True LD, Buhler K, Quinn J, et al. A neuroendocrine/ small cell prostate carcinoma xenograft - LuCaP 49. Am J Pathol 2002;161:705-715.
22. Wang Z, Hao Y, Lowe AW. The adenocarcinomaassociated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008;68:492-497.
23. Ramachandran V, Arumugam T, Wang H, et al. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008;68:7811-7818.
24. Vanderlaag KE, Hudak S, Bald L, et al. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and surviving. Breast Cancer Res 2010; 12:R32.
25. Park K, Chung YJ, So H, et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 2011;43:91-100.
26. Dumartin L, Whiteman HJ, Weeks ME, et al. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 2011;71:7091-7102.
27. Zweitzig DR, Smirnov DA, Connelly MC, et al. Physiological stress induces the metastasis marker AGR2 in breast cancer cells. Mol Cell Biochem 2007;306:255-260.
28. Patel BJ, Pantuck AJ, Zisman A, et al. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol 2000;164:1420-1425.
29. Chen ME, Lin SH, Chung LW, et al. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 1998;273:17618-17625.
30. Kaighn ME, Lechner JF, Babcock MS, et al. The Pasadena cell lines. Prog Clin Biol Res 1980;37: 85-109.
31. Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55:71-80.
32. Zhang Y, Forootan SS, Liu D, et al. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007;10: 293-300.
33. Barraclough DL, Platt-Higgins A, de Silva Rudland S, et al. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol 2009;175:1848-1857.
34. Fritzsche FR, Dahl E, Pahl S, et al. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 2006;12:1728-1734.